Colchicine Binding Site Tubulin Inhibitors Impair Vincristine-Resistant Neuroblastoma Cell Function

Area of Science:

• Pediatric Oncology
• Cancer Biology
• Pharmacology

Background:

• High-risk neuroblastoma has a poor prognosis, with limited treatment options and frequent resistance to standard chemotherapy like vincristine.
• Vincristine resistance is a major challenge in neuroblastoma treatment, necessitating the development of alternative therapeutic strategies.
• Tubulin inhibitors targeting the colchicine binding site (CBSIs) represent a promising class of drugs with potential to overcome existing resistance mechanisms.

Purpose of the Study:

• To evaluate the efficacy of novel colchicine binding site inhibitors (CBSIs) against various neuroblastoma cell lines, including those resistant to vincristine.
• To investigate the impact of CBSI treatment on cell division and apoptotic cell death in both sensitive and resistant neuroblastoma cells.
• To explore the potential of CBSIs as a therapeutic approach for overcoming vincristine resistance in high-risk neuroblastoma.

Main Methods:

• Treatment of multiple neuroblastoma cell lines (vincristine-sensitive and -resistant) with newly developed CBSIs.
• Assessment of cell division disruption and cellular activity in response to CBSI treatment.
• Analysis of differential apoptotic cell death induction in vincristine-resistant cell lines upon CBSI exposure.

Main Results:

• The novel CBSIs effectively disrupted cell division in both vincristine-sensitive and -resistant neuroblastoma cell lines.
• Demonstrated cellular activity of CBSIs against neuroblastoma cells that exhibit resistance to vincristine.
• Observed variations in the capacity of vincristine-resistant cell lines to undergo apoptosis following CBSI treatment, indicating distinct resistance mechanisms.

Conclusions:

• Newly developed colchicine binding site inhibitors (CBSIs) exhibit significant anti-cancer activity against neuroblastoma, including vincristine-resistant forms.
• CBSIs show potential as a novel therapeutic strategy to overcome treatment resistance in high-risk neuroblastoma.
• Further investigation into CBSI utility and the distinct resistance mechanisms in neuroblastoma is warranted for improved pediatric cancer treatment.